Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
62 400
214 000
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Sam Chun Dang Pharm Co Ltd stock under the Base Case scenario is 11 241.66 KRW. Compared to the current market price of 104 800 KRW, Sam Chun Dang Pharm Co Ltd is Overvalued by 89%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Sam Chun Dang Pharm Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Sam Chun Dang Pharm Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2000-10-04. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Sam Chun Dang Pharm Co Ltd
Balance Sheet Decomposition
Sam Chun Dang Pharm Co Ltd
Current Assets | 239B |
Cash & Short-Term Investments | 150B |
Receivables | 36.8B |
Other Current Assets | 52.2B |
Non-Current Assets | 254.2B |
Long-Term Investments | 30.5B |
PP&E | 96.5B |
Intangibles | 109.2B |
Other Non-Current Assets | 18.1B |
Current Liabilities | 58.3B |
Accounts Payable | 4.6B |
Accrued Liabilities | 10.9B |
Short-Term Debt | 22.5B |
Other Current Liabilities | 20.3B |
Non-Current Liabilities | 159.5B |
Long-Term Debt | 36.4B |
Other Non-Current Liabilities | 123B |
Earnings Waterfall
Sam Chun Dang Pharm Co Ltd
Revenue
|
208.2B
KRW
|
Cost of Revenue
|
-109.5B
KRW
|
Gross Profit
|
98.7B
KRW
|
Operating Expenses
|
-94.5B
KRW
|
Operating Income
|
4.2B
KRW
|
Other Expenses
|
884m
KRW
|
Net Income
|
5.1B
KRW
|
Free Cash Flow Analysis
Sam Chun Dang Pharm Co Ltd
KRW | |
Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
Sam Chun Dang Pharm Co Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Sam Chun Dang Pharm Co Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Sam Chun Dang Pharm Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Sam Chun Dang Pharm Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Sam Chun Dang Pharm Co Ltd
Dividends
Current shareholder yield for Sam Chun Dang Pharm Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one Sam Chun Dang Pharm Co Ltd stock under the Base Case scenario is 11 241.66 KRW.
Compared to the current market price of 104 800 KRW, Sam Chun Dang Pharm Co Ltd is Overvalued by 89%.